Jun 10, 2020 / 06:10PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD
Great. Good afternoon, everybody. I'm Terence Flynn, a biopharma analyst at Goldman Sachs. Today, we're very pleased to be hosting Eli Lilly. Joining us from the company is Josh Smiley, the CFO; and Mike Czapar, who's Director of Investor Relations. Thank you both for joining us today. We really appreciate the time.
Questions and Answers:
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MDJust to start at a high level, COVID-19 has obviously been front and center and is going to have near and long-term impacts on the health care system and companies' business models, if we look at delivery of care, clinical trial conduct or the supply chain. So I would be curious, Josh, to get your take on any preliminary perspectives you could share with respect to the ways which COVID might change your business model or strategy.
Joshua L. Smiley - Eli Lilly and Company - Senior VP & CFO
Sure. Thank you. Thanks, Terence. And thanks for